Antihypertensive therapy and renal function

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 3, 1996, Pages

  Mimran, Albert ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Antihypertensive agents; Essential hypertension; Nephrosclerosis; Renal function

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; METOPROLOL; MOXONIDINE; NIFEDIPINE; PRAZOSIN; RAMIPRIL; SODIUM CHANNEL AFFECTING AGENT; VERAPAMIL;

ARTERIAL PRESSURE; CONFERENCE PAPER; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RELIABILITY;

EID: 0029787368     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199627003-00004     Document Type: Conference Paper

References (47)

1. Ribstein J, Codis P, Du Cailar G, Mimran A. Effects of captopril and nitrendipine on the response to acute volume expansion in essential hypertension. J Hypertens 1988;6 (suppl 4):S473-5.
2. Du Cailar G, Ribstein J, Daures JP, Mimran A. Sodium and left ventricular mass in untreated hypertensive and normotensive subjects. Am J Physiol 1992;263:H177-81.
3. Pasquié JL, Jover B, Du Cailar G, Mimran A. Sodium but not chloride ion modulates left ventricular hypertrophy in two-kidney, one clip hypertension. J Hypertens 1994;12:1013-8.
4. O'Connor DT. Response of the renal kallikrein-kinin system, intravascular volume, and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension. Hypertension 1982;4(suppl 3):72-8.
5. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991;18:805-12.
6. Benstein JA, Feiner HD, Parker M, Dworkin LD. Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. Am J Physiol 1990;258:F1675-81.
7. O'Connor DT, Preston RA, Mitas JA, Frigon RP, Stone RA. Urinary kallikrein activity and renal vascular resistance in the antihypertensive response to thiazide diuretics. Hypertension 1981;3:139-47.
8. Van Brummelen P, Woerlee M, Schalekamp MADH. Long-term versus short-term effects of hydrochlorothiazide on renal haemodyamics in essential hypertension, Clin Sci 1979;56:463-9.
9. Toto RD, Mitchell HC, Lee HC, Milam C, Pettinger WA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991;115:513-9.
10. Bianchi S, Bigazzi R, Baldari G, Campese VM. Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. Am J Med 1992;93:525-8.
11. Hallab M, Gallois Y, Chatellier G, Rohmer V, Fressinaud P, Marre M. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ 1993;306:175-82.
12. Wilkins MR, Unwin RJ, Kenny AJ. Endopeptidase-24.11 and its inhibitors: potential therapeutic agents foredematous disorders and hypertension. Kidney Int 1993;43:273-85.
13. Bauer JH, Jones LB, Gaddy P. Effects of prazosin therapy on BP. renal function, and body fluid composition. Arch Intern Med 1984;144:1196-200.
14. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993;21:810-5.
15. Bauer JH. Effects of propranolol therapy on renal function and body fluid composition. Arch Intern Med 1983;143:927-31.
16. Falch DK, Paulsen AQ, Odegaard AE, Norman N. Central and renal circulation, electrolyte, body weight and renin during atenolol treatment in essential hypertension. Curr Ther Res 1979;26:813-20.
17. Textor SC, Fouad FM, Bravo EL, Tarazi RC, Vidt DG. Redistribution of cardiac output to the kidneys during oral nadolol administration. N Engl J Med 1982;307:601-5.
18. Bauer JH, Reams GP, Lau A. A comparison of betaxolol and nadolol on renal function in essential hypertension. Am J Kidney Dis 1987;10:109-12.
19. Ribstein J, Du Cailar G, Brouard R, Mimran A. Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension. Cardiology 1993;83(suppl 1):57-63.
20. Onesti G, Bock KD, Heimsoth V, Kim KE, Merguet P. Clonidine: a new antihypertensive agent. Am J Cordiol 1971;28:74-83.
21. Fliser D, Wiecek A, Ritz E. Renal hemodynamics. Cardiovasc Risk Factors 1995;5(suppl 1):-40-4.
22. Irzyniec T, Mall G, Greber D, Ritz E. Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 1992;5:437-43.
23. Persson B, Wysocki M, Andersson OK. Long-term renal effects of isradipine, a calcium entry blocker, in essential hypertension. J Cardiovasc Pharmacol 1989;14:22-4.
24. Pedersen OL, Krusell LR, Sihm I, Jespersen LT, Thomsen K. Long-term effects of isradipine on blood pressure and renal function. Am J Med 1989;86(suppl 4A):15-8.
25. Sunderrajan S, Reams G, Bauer JH. Renal effects of diltiazem in primary hypertension. Hypertension 1986;8:238-42.
26. Katzman PL, Henningsen NC, Fagher B, Thulin T, Lennart Hulthén U. Renal and endocrine effects of long-term converting enzyme inhibition as compared with calcium antagonism in essential hypertension. J Cardiovasc Pharmacol 1990;15:360-4.
27. Reams GP, Hamory A, Lau A, Bauer JH. Effect of nifedipine on renal function in patients with essential hypertension. Hypertension 1988;11:452-6.
28. Reams GP, Lau A, Hamory A, Bauer JH. Amlodipine therapy corrects renal abnormalities encountered in the hypertensive state. Am J Kidney Dis 1987;10:446-51.
29. Wittenberg C, Rosenfeld JB. Long-term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function. J Cardiovasc Pharmacol 1992;19(suppl 3):S93-5.
30. Pevahouse JB, Markandu ND, Cappuccio FP, Buckley MG, Sagnella GA, MacGregor GA. Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure. BMJ 1990;301:580-4.
31. Diamond JR, Cheung JY, Fang LST. Nifedipine-induced renal dysfunction. Alterations in renal hemodynamics. Am J Med 1984;77:905-9.
32. Mimran A, Ribstein J. Angiotensin converting enzyme inhibitors and renal function. J Hypertens 1989;7(suppl 5):S3-9.
33. Mimran A, Ribstein J, Du Cailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens 1991;4:78-148.
34. Mimran A, Ribstein J, Du Cailar G. Is microalbuminuria a marker of early intrarenal vascular dysfunction in essential hypertension? Hypertension 1994;23(Pt 2):1018-21.
35. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.
36. Kawabata M, Takabatake T, Ohta H, et al. Effects of an angiotensin II receptor antagonist. TCV-116, on renal haemodynamics in essential hypertension. Blood Pressure 1994;3(suppl 5):117-21.
37. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994;45:861-7.
38. Weir MR. Hypertensive nephropathy: is a more physiologic approach to blood pressure control an important concern for the preservation of renal function? Am J Med 1992;93(suppl 2A):27S-37S.
39. Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio JL. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990;8:525-31.
40. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989;320:684-8.
41. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987;31:673-89.
42. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
43. Ribstein J, Du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995;26:610-5.
44. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994;23:195-9.
45. Schmieder RE, Veelken R, Gatzka CD, Rüddel H, Schächinger H. Predictors for hypertensive nephropathy: results of a 6-year follow-up study in essential hypertension. J Hypertens 1994;13:357-65.
46. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1988;1:335-47.
47. Toto RD, Mitchell HC, Smith RD, Lee HC, McIntire D, Pettinger WA. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995;48:851-9.